SUPN — Supernus Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	580	667	608	662	719
Cost of Revenue
Gross Profit	505	580	524	593	646
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	494	621	613	580	781
Operating Profit	86	46.1	-5.27	81.7	-62.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	73.2	60.7	2.77	97.9	-49
Provision for Income Taxes
Net Income After Taxes	53.4	60.7	1.32	73.9	-38.5
Net Income Before Extraordinary Items
Net Income	53.4	60.7	1.32	73.9	-38.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	53.4	64.3	1.32	73.9	-38.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.28	1.04	0.197	1.44	0.179